In this study, we showed that HGF, which can be produced by fibroblasts in the tumor microenvironment, induces entrectinib resistance by activating its receptor MET and downstream signaling pathways in NTRK1‐rearranged or ROS1‐rearranged tumor cells. Here, ROS1 is linked to neoplasm.